Guggenheim Lifts Insmed Price Target to $230 Following Biotech Earnings Model Update

Guggenheim has raised its price target for Insmed Incorporated (INSM) to $230 after updating its earnings models for the biotech industry. This indicates a positive re-evaluation of the company's financial prospects.